

## **MedMira Inc.**

Condensed Interim Consolidated Financial Statements  
For the six months ended January 31, 2017 and January 31, 2016  
(Unaudited – Prepared by Management)

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the period ending January 31, 2017

---

**March 31, 2017**

**Management's responsibility for financial reporting**

The accompanying consolidated financial statements of MedMira Inc. (MedMira or the Company) are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards (IFRS). The consolidated financial statements includes amounts and assumptions based on management's best estimates which have been derived with careful judgement.

In fulfilling its responsibilities, management has developed and maintains a system of internal accounting controls. These controls are designed to ensure that the financial records are reliable for preparation of the consolidated financial statements.

The Board of Directors of the Company is responsible for ensuring that management fulfils its responsibilities for financial reporting and is ultimately responsible for reviewing and approving the condensed interim consolidated financial statements and the accompanying management's discussion and analysis. The Board of Directors carries out this responsibility principally through its Audit Committee.

The Audit Committee is a subcommittee of the Board of Directors. It is responsible for oversight of the internal control and financial matters assisting the Company's management and independent auditors to ensure that the integrity of the financial reporting process is maintained.

(signed) *Hermes Chan*  
Chief Executive Officer

(signed) *Markus Meile*  
Chief Financial Officer

**Unaudited consolidated statements of financial position**  
**As at January 31, 2017 and July 31, 2016**

*In Canadian dollars*

	<i>Notes</i>	<b>31-Jan-17</b>	<b>31-Jul-16</b>
		\$	\$
<b>Assets</b>			
<i>Current assets</i>			
Cash		118,682	46,120
Trade and other receivables		94,357	186,394
Prepaid expenses		80,507	52,470
Current tax assets		100,000	100,000
Inventories	4	<u>280,853</u>	<u>293,456</u>
Total current assets		<u>674,399</u>	<u>678,440</u>
<i>Non-current assets</i>			
Property, plant and equipment		141,920	191,463
Intangible assets		<u>2</u>	<u>2</u>
Total non-current assets		<u>141,922</u>	<u>191,465</u>
<b>Total assets</b>		<u><u>816,321</u></u>	<u><u>869,905</u></u>
<b>Liabilities</b>			
<i>Current liabilities</i>			
Current portion of debt	7	5,958,455	5,994,445
Accounts payable and accrued liabilities		2,252,061	2,241,257
Deferred revenue		<u>7,264</u>	<u>41,297</u>
Total current liabilities		<u>8,217,780</u>	<u>8,276,999</u>
<i>Non-current liabilities</i>			
Long term portion of debt	7	<u>285,927</u>	<u>255,065</u>
Total non-current liabilities		<u>285,927</u>	<u>255,065</u>
<b>Total liabilities</b>		<u>8,503,707</u>	<u>8,532,064</u>
<b>Equity</b>			
Share capital	5	63,421,802	63,421,802
Warrant reserve	5	9,966,770	9,966,770
Stock based compensation reserve	5	1,353,292	1,337,206
Equity reserve	9	2,375,870	1,065,770
Accumulated deficit		<u>(84,805,120)</u>	<u>(83,453,707)</u>
<b>Total shareholders' deficiency</b>		<u>(7,687,386)</u>	<u>(7,662,159)</u>
<b>Total liabilities and equity</b>		<u><u>816,321</u></u>	<u><u>869,905</u></u>

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**Approved on behalf of the Board of Directors**

(signed) *Hermes Chan*, Director

(signed) *Romano Robusto*, Director

**Unaudited consolidated statements of operations and comprehensive (loss) income**  
**For the six months ended January 31, 2017 and January 31, 2016**

*In Canadian dollars*

	<i>Notes</i>	<b>for the three months ended</b>		<b>for the six months ended</b>	
		<b>31-Jan-17</b>	<b>31-Jan-16</b>	<b>31-Jan-17</b>	<b>31-Jan-16</b>
		<b>\$</b>	<b>\$</b>	<b>\$</b>	
<b>Product</b>					
Product sales	3	193,576	190,118	405,821	508,970
Product cost of sales		<u>(59,924)</u>	<u>(70,503)</u>	<u>(152,567)</u>	<u>(145,628)</u>
<b>Gross margin on product</b>		<u>133,652</u>	<u>119,615</u>	<u>253,254</u>	<u>363,342</u>
<b>Services</b>					
Service sales	3	-	1,180,037	-	2,474,729
Service cost of sales		<u>-</u>	<u>(1,063,632)</u>	<u>-</u>	<u>(2,016,265)</u>
<b>Gross margin on services</b>		<u>-</u>	<u>116,405</u>	<u>-</u>	<u>458,464</u>
<b>Operating expenses</b>					
Research and development	10	58,011	(164,282)	(108,673)	(744,413)
Sales and marketing		(122,616)	(206,676)	(279,698)	(377,902)
Other direct costs		(175,312)	(200,261)	(345,283)	(368,013)
General and administrative		<u>(322,610)</u>	<u>(480,237)</u>	<u>(655,954)</u>	<u>(856,849)</u>
<b>Total operating expenses</b>		<u>(562,527)</u>	<u>(1,051,456)</u>	<u>(1,389,608)</u>	<u>(2,347,177)</u>
<b>Operating loss</b>		<u>(428,875)</u>	<u>(815,436)</u>	<u>(1,136,354)</u>	<u>(1,525,371)</u>
<b>Non-operating income (expenses)</b>					
Financing		<u>(120,729)</u>	<u>(166,303)</u>	<u>(215,059)</u>	<u>(356,784)</u>
<b>Net (loss) income</b>		<u>(549,604)</u>	<u>(981,739)</u>	<u>(1,351,413)</u>	<u>(1,882,155)</u>
Basic (loss) earnings per share	6	(0.00083)	(0.00149)	(0.00205)	(0.00286)
Diluted (loss) earnings per share	6	(0.00083)	(0.00149)	(0.00205)	(0.00286)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**Unaudited consolidated statements of changes in equity attributable to equity holders of the Company**

*In Canadian dollars*

	Share capital					Accumulated deficit	Shareholders' deficiency	
	Notes	Common shares	Preferred shares	Warrant reserve	Option reserve			Equity reserve
<b>Balance at July 31, 2015</b>		<b>60,208,678</b>	<b>2,500</b>	<b>8,202,394</b>	<b>1,311,597</b>	<b>865,770</b>	<b>(78,295,306)</b>	<b>(7,704,367)</b>
Net and comprehensive income		-	-	-	-	-	(1,882,155)	(1,882,155)
Issuance of common shares and warrants for cash		3,235,624	-	1,764,376	-	-	-	5,000,000
Share issuance costs		(25,000)	-	-	-	-	-	(25,000)
Issuance of stock options		-	-	-	25,609	-	-	25,609
<b>Balance at January 31, 2016</b>		<b>63,419,302</b>	<b>2,500</b>	<b>9,966,770</b>	<b>1,337,206</b>	<b>865,770</b>	<b>(80,177,461)</b>	<b>(4,585,913)</b>
Net and comprehensive loss		-	-	-	-	-	(3,276,246)	(3,276,246)
Issuance of common shares and warrants for cash		-	-	-	-	-	-	-
Issuance of common shares and warrants for debt		-	-	-	-	-	-	-
Share issuance costs		-	-	-	-	-	-	-
Issuance of stock options		-	-	-	-	-	-	-
Funding under royalty agreement		-	-	-	-	200,000	-	200,000
<b>Balance at July 31, 2016</b>		<b>63,419,302</b>	<b>2,500</b>	<b>9,966,770</b>	<b>1,337,206</b>	<b>1,065,770</b>	<b>(83,453,707)</b>	<b>(7,662,159)</b>
Net and comprehensive loss		-	-	-	-	-	(1,351,413)	(1,351,413)
Issuance of common shares and warrants for cash		-	-	-	-	-	-	-
Share issuance costs		-	-	-	-	-	-	-
Issuance of stock options		-	-	-	16,086	-	-	16,086
Funding under royalty agreement		-	-	-	-	1,310,100	-	1,310,100
<b>Balance at January 31, 2017</b>		<b>63,419,302</b>	<b>2,500</b>	<b>9,966,770</b>	<b>1,353,292</b>	<b>2,375,870</b>	<b>(84,805,120)</b>	<b>(7,687,386)</b>

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**Unaudited consolidated statements of cash flows**  
**For the six months ended January 31, 2017 and January 31, 2016**  
*In Canadian dollars*

	31-Jan-17 \$	31-Jan-16 \$
<b>Cash flow from operating activities</b>		
Loss for the six month period	(1,351,413)	(1,882,155)
Adjustments for		
Depreciation	49,543	49,341
Stock based compensation expense	16,086	25,609
Accretion expense	-	189,939
	<u>(1,285,784)</u>	<u>(1,617,266)</u>
Movements in working capital:		
(Increase)/decrease in trade and other receivables	92,037	(650,208)
(Increase)/decrease in inventories	12,603	(21,167)
(Increase)/decrease in prepaids	(28,037)	(86,299)
(Increase)/decrease in trade and other payables	10,804	(217,150)
(Increase)/decrease in deferred revenue	<u>(34,033)</u>	<u>10,867</u>
Net cash generated by operating activities	<u>(1,232,410)</u>	<u>(2,581,223)</u>
<b>Cash flows from investing activities</b>		
Payment to acquire property, plant and equipment	-	(27,250)
Net cash from investing activities	<u>-</u>	<u>(27,250)</u>
<b>Cash flow from financing activities</b>		
Proceeds from the issuance of common shares	-	5,000,000
Payments for share issue costs	-	(25,000)
Funding under royalty agreements	1,310,100	-
Proceeds from borrowings	30,861	1,184,935
Repayment of borrowing	<u>(35,989)</u>	<u>(2,181,006)</u>
Net cash from financing activities	<u>1,304,972</u>	<u>3,978,929</u>
Net increase in cash and cash equivalents	72,562	1,370,456
Cash and cash equivalents at the beginning of the period	<u>46,120</u>	<u>262,392</u>
Cash at the end of the period	<u>118,682</u>	<u>1,632,848</u>

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

MedMira Inc.

Notes to the unaudited condensed interim consolidated financial statements

For the six months ended January 31, 2017 and January 31, 2016

In Canadian dollars

## 1. Reporting entity

### Nature of operations

MedMira Inc. (MedMira or the Company) is a biotechnology company headquartered in Canada. The address of the Company's registered office is 155 Chain Lake Drive, Suite 1, Halifax, Nova Scotia, B3S 1B3. MedMira Holding AG owns the majority of MedMira's shares and is the controlling shareholder. MedMira, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. MedMira's research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and *in vitro* sectors.

## 2. Significant accounting policies

### a. Basis of presentation

The condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting, using the same basis of measurement and presentation and the same accounting policies as described in notes 2 and 3 to the Company's audited consolidated financial statements as at and for the year ended July 31, 2016, except as noted below. The condensed interim consolidated financial statements should be read in conjunction with those audited consolidated financial statements.

The condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries which are shown below.

	Country of incorporation	Ownership interest	
		%	%
		January 31, 2017	July 31, 2016
MedMira Inc.	Canada	100	100
MedMira Laboratories Inc.	Canada	100	100
Maple Biosciences Inc.	Canada	100	100
MedMira International AG	Switzerland	100	100
MedMira (US) Inc.	United States of America	100	100

The condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its subsidiaries. All financial information is presented in Canadian dollars unless explicitly stated.

The condensed interim consolidated financial statements were authorized for issue by the Board of Directors on March 31, 2017.

### b. Going-concern

The condensed interim consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations. However, certain adverse conditions and events cast significant doubt upon the validity of this assumption.

The Company has incurred losses and negative cash flows from operations on a cumulative basis since inception. For the six months ended January 31, 2017, the Company realized a net loss of approximately \$1.4 million (January 31, 2016 – net loss of \$1.9 million), consisting of a net loss from operations of \$1.1 million (January 31, 2016 – net loss \$1.5 million), and other non-operating expenses of \$0.2 million (January 31, 2016 – loss of \$0.4 million). Negative cash flows from operations were approximately \$1.2 million (January 31, 2016 – \$1.5 million). As at January 31, 2017, the Company had an accumulated deficit of approximately \$84.8 million (July 31, 2016 – \$83.5 million). In addition to its on-going working capital requirements, the Company must secure sufficient funding for its research and development programs for existing commitments, including its current portion of loans of approximately \$6.0 million. These circumstances lend significant doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going-concern.

Management is pursuing other financing alternatives to fund the Company's operations so it can continue as a going-concern. Management plans to secure the necessary financing through new equity and debt arrangements. Nevertheless, there is no assurance that this initiative will be successful.

The Company is subject to risks associated with early stage companies, including but not limited to, dependence on key individuals, competition from substitute services and larger companies, and the requirement for the continued successful development and marketing of its products and services. The Company's ability to continue as a going-concern is dependent upon its ability to generate positive cash flow from operations and secure additional financing. These financial statements do not reflect the adjustments to carrying values of assets and liabilities and the reported expenses and balance sheet classifications that would be necessary were the going-concern assumption not appropriate. These adjustments could be material.

c. Future changes in accounting policies

The following new standards and amendments have been issued but are not effective for the six months ended January 31, 2017, and, accordingly, have not been applied in preparing these consolidated financial statements.

*IFRS 9 - Financial Instruments* - A finalized version of IFRS 9 which contains accounting requirements for financial instruments, replacing IAS 39 Financial Instruments: Recognition and Measurement has been issued and is effective for annual periods beginning on or after January 1, 2018. The standard contains requirements in the following areas: classification and measurement, impairment, hedge accounting and derecognition. This new standard supersedes all prior versions of IFRS 9.

*IFRS 15 - Revenue from Contracts with Customers*. This standard is effective from fiscal years beginning on or after January 1, 2018 and provides a single, principles based five-step model to be applied to all contracts with customers. Guidance is provided on topics such as the point in which revenue is recognized, accounting for variable consideration, costs of fulfilling and obtaining a contract and various related matters. New disclosures about revenue are also introduced.

*IFRS 16 – Leases*. This standard provides a single lease accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12 months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and financial leases being retained. IFRS 16 is effective for annual periods beginning on or after January 1, 2019. Early adoption is permitted if IFRS 15 has also been applied.



*IFRS 2 – Share –based payments.* The amendment clarifies how to account for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments, share-based payment transactions with a net settlement feature and a modification to the terms and conditions that changes the classification of the transactions. The amendment is effective for annual periods beginning on or after January 1, 2018

The Company is currently evaluating the potential impact, if any, of these standards and amendments.

### 3. Revenue

	for the three months ended		for the six months ended	
	31-Jan-17	31-Jan-16	31-Jan-17	31-Jan-16
			\$	\$
Product sales	193,576	190,118	405,821	508,970
Service revenue	-	1,180,037	-	2,474,729
<b>Total revenue</b>	<u>193,576</u>	<u>1,370,155</u>	<u>405,821</u>	<u>2,983,699</u>

Service revenue was generated from research work on a contract with the U.S. military. The costs associated with research conducted to earn this revenue have been recognized as a service cost of sales.

The Company organizes and records revenue based on major geographical territories around the world. The table below provides the geographic breakdown of revenue.

	for the three months ended		for the six months ended	
	31-Jan-17	31-Jan-16	31-Jan-17	31-Jan-16
			\$	\$
North America	161,208	1,300,918	248,500	2,828,733
Latin America and the Caribbean	-	58,332	96,911	123,611
Asia Pacific	26,025	6,125	33,083	9,786
Europe	6,343	4,780	27,327	21,569
<b>Total revenue</b>	<u>193,576</u>	<u>1,370,155</u>	<u>405,821</u>	<u>2,983,699</u>

#### 4. Inventories

As at January 31, 2017, there were no valuation allowances against inventory (July 31, 2016 – \$nil).

During the six months ended January 31, 2017, inventory valued at \$134,534 was expensed as a cost of goods sold (January 31, 2016 – \$113,287).

	31-Jan-17	31-Jan-16
	\$	\$
Raw materials and consumables	218,878	241,352
Work in process	41,992	66,410
Finished goods	19,983	13,333
<b>Total inventories</b>	<u>280,853</u>	<u>321,095</u>

#### 5. Capital and other components of equity

##### a. Authorized

The Company is authorized to issue an unlimited number of Series A preferred shares, non-voting, non-participating, redeemable at the Company's option at \$0.001 per share after March 31, 2010, convertible into an equal number of common shares upon the Company meeting certain milestones. The preferred shares earn no dividends.

The Company is authorized to issue an unlimited number of voting common shares without nominal or par value.

##### b. Share capital issued

	Number of		Value of		
	Common shares	Preferred shares	Common shares \$	Preferred shares \$	Total share capital \$
<b>Balance at July 31, 2016</b>	<b>658,364,320</b>	<b>5,000,000</b>	<b>63,419,302</b>	<b>2,500</b>	<b>63,421,802</b>
Issued for cash	-	-	-	-	-
Share issuance costs	-	-	-	-	-
<b>Balance at January 31, 2017</b>	<b>658,364,320</b>	<b>5,000,000</b>	<b>63,419,302</b>	<b>2,500</b>	<b>63,421,802</b>

The total common shares issued and outstanding include 4,064,464 common shares held in escrow scheduled to be released when the Company obtains positive operating cash flow.

The Series A preferred shares had a stated capital of \$2,500 at January 31, 2017 (July 31, 2016 – \$2,500).

MedMira Inc.

Notes to the unaudited condensed interim consolidated financial statements

For the six months ended January 31, 2017 and January 31, 2016

In Canadian dollars

c. Warrants

	Number of warrants	Warrant reserve \$
<b>Balance at July 31, 2016</b>	<b>266,100,000</b>	<b>9,966,770</b>
Issued for cash	-	-
<b>Balance at January 31, 2017</b>	<b>266,100,000</b>	<b>9,966,770</b>

The total warrants outstanding at January 31, 2017 are shown below.

Issued	Number	Exercise price \$	Expiry date
September 30, 2013	122,100,000	0.10	September 30, 2017
October 2, 2014	22,000,000	0.10	October 2, 2018
March 27, 2015	22,000,000	0.10	March 27, 2019
September 8, 2015	<u>100,000,000</u>	0.10	September 8, 2019
	266,100,000		

d. Stock based compensation

The Company has established a stock option plan for its employees, officers, and directors. All options vest immediately upon issue and the Company is authorized to issue a maximum of 13,000,000 options annually upon approval by shareholders. Options that have been issued and remain outstanding are exercisable into an equivalent of 3,269,792 common shares (July 31, 2016 – 2,094,792) at an exercise price of \$0.10. The options expire between March 2, 2017 and January 29, 2020. All options outstanding at January 31, 2017 were exercisable.

	Number	Weighted average exercise price \$	Equity Reserve \$
<b>Options Outstanding July 31, 2016</b>	<b>2,094,792</b>	<b>0.10</b>	<b>1,337,206</b>
Options expired/forfeit	-	-	-
Options granted	1,175,000	0.10	16,086
<b>Options outstanding January 31, 2017</b>	<b>3,269,792</b>		<b>1,353,292</b>

The following table summarizes information about options outstanding and exercisable at January 31, 2017.

Range of exercise prices	Number outstanding and exercisable	Weighted average exercise price per share	Weighted average remaining contractual life (years)
0.10	3,269,792	0.10	1.79

## 6. Earnings (loss) per share

	For the three months ended		For the six months ended	
	31-Jan-17	31-Jan-16	31-Jan-17	31-Jan-16
			\$	\$
Net income (loss) attributable to common shareholders	(549,604)	(981,739)	(1,351,413)	(1,882,155)
Issued common shares	658,364,320	658,364,320	658,364,320	658,364,320
Weighted average number of common shares	658,364,320	658,364,320	658,364,320	658,364,320
Basic earnings (loss) per share	(0.00083)	(0.00149)	(0.00205)	(0.00286)
Diluted earnings (loss) per share	(0.00083)	(0.00149)	(0.00205)	(0.00286)

Basic and diluted (loss) earnings per share are the same for the three months ended January 31, 2017 and January 31, 2016 as the exercise of potentially dilutive instruments would be anti-dilutive.

## 7. Loans and borrowings

	31-Jan-17		31-Jul-16	
	Carrying value	Contract value	Carrying value	Contract value
	\$	\$	\$	\$
Loan 1	1,054,167	1,054,167	1,054,167	1,054,167
Loan 2	1,300,000	1,300,000	1,300,000	1,300,000
Loan 3	-	-	3,000	3,000
Loan 4	-	-	3,495	3,495
Loan 5	13,500	13,500	13,500	13,500
Loan 6	242,427	242,427	241,565	241,565
Loan 7	15,000	15,000	-	-
Loan 8	15,000	15,000	-	-
ACOA loans	490,898	490,898	520,393	520,393
Nova Scotia Government loan 1	3,016,000	3,016,000	3,016,000	3,016,000
Nova Scotia Government loan 2	97,390	97,390	97,390	97,390
<b>Total loan principal</b>	<b>6,244,382</b>	<b>6,244,382</b>	<b>6,249,510</b>	<b>6,249,510</b>
Long term portion of principal	285,927		255,065	
Current portion payable of principal	5,958,455		5,994,445	

### Loan 1

Loan established October 31, 2012, bearing 5% interest with monthly interest only payments until November 30, 2013, followed by equal monthly principal payments and accrued interest for five additional years ending November 30, 2018. The loan is secured by interest on intellectual property and on the step-up technology. The loan was in default due to non payment of interest and principal payments as of January 31, 2017 and thus has been classified as a current liability.

### Loan 2

Loan established July 31, 2012, bearing 5% interest with monthly interest only payments until July 31, 2013, followed by equal monthly principal payments for five additional years ending July 31, 2018. During fiscal 2016 the loan was renegotiated. Monthly interest payments are due until April 30, 2016, followed by equal monthly principal payments and accrued interest for four additional years ending July 31, 2020. The loan is in default due to non payment of interest and principal payments as of January 31, 2017 and thus has been classified as a current liability.

### Loan 3

Loan established July 31, 2012, bearing 5% interest with monthly principal payments of \$1,000, and accrued monthly interest ending September 30, 2016. The loan was fully repaid during the six months ended January 31, 2017.

*Loan 4*

Loan established February 11, 2016, bearing 5% interest. The loan was fully repaid during the six months ended January 31, 2017.

*Loan 5*

Loan established June 10, 2016, bearing 5% interest. The loan is fully payable on or before August 31, 2018. The loan was not in default at January 31, 2017.

*Loan 6*

Loan established January 21, 2017, bearing 5% interest. The loan is fully payable on or before October 1, 2018. The loan was not in default at January 31, 2017.

*Loan 7*

Loan established August 2, 2016, bearing 5% interest. The loan is fully payable on or before August 31, 2018. The loan was not in default at January 31, 2017.

*Loan 8*

Loan established August 11, 2016, bearing 5% interest. The loan is fully payable on or before August 31, 2018. The loan was not in default at January 31, 2017.

*Atlantic Canada Opportunities Agency (ACOA) loan*

Loans were negotiated on October 31, 2012, bearing no interest with monthly principal repayments of \$3,747 until July 31, 2013, followed by equal monthly principal payments of \$24,234 for five additional years ending July 31, 2018. The loan was renegotiated in July 2014, bearing no interest with a monthly principal payment of \$24,234 in August 2014 followed by 40 monthly payment of \$27,800 starting on February 1, 2015 and one monthly payment of \$26,975 at the end of the loan. The loan is secured by all present and after acquired personal property, excepting consumer goods. The loans were in default due to non payment of principal at January 31, 2017 and thus have been classified as a current liability.

*Nova Scotia Government loan 1*

The loan was negotiated in August 2015, bearing interest based on the Province of Nova Scotia's five year cost of funds plus five hundred basis points. Monthly interest payments are due until August 31, 2018. Starting on September 1, 2016, thirteen monthly principal payments of \$120,000 are due followed by ten monthly principal payments of \$135,000 starting on October 1, 2017 and one monthly principal payment of \$106,000 on August 1, 2018. The loan is secured by first interest on intellectual property and on the Maple bio sensor technology. The loan was in default due to non payment of interest and principal at January 31, 2017 and thus has been classified as a current liability.

*Nova Scotia Government loan 2*

Loan established September 14, 2012, bearing no interest with the balance due by August 31, 2018. The loan is secured by first interest on intellectual property and on the Maple BioSciences Inc. sensor technology. The loan was

in default due to non payment of interest and principal at January 31, 2017 and thus has been classified as a current liability.

## 8. Financial instruments

### a. Foreign currency risk

Most of the Company's sales are made in foreign currencies. The Company's U.S. dollar foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are shown in the table below.

	31-Jan-17 US\$	31-Jul-16 US\$
Cash and cash equivalents	55,848	24,148
Trade and other receivables	57,265	128,424
Prepaid expense	17,543	5,949
Accounts payable and accrued liabilities	850,296	943,411

A one cent change in the U.S. dollar exchange rate would result in approximately a \$7,196 (July 31, 2016 – \$11,020) impact on the balance sheet and consolidated statement of income.

### b. Liquidity risk

Liquidity risk represents the possibility that the Company may not be able to gather sufficient cash resources, when required and under reasonable conditions, to meet its financial obligations. As at January 31, 2017, the Company does not have sufficient cash to meet all of its continual liabilities.

The Company also continues to have an ongoing need for substantial capital resources to research and develop, commercialize and manufacture its products and technologies. The Company is not yet generating a sufficient ongoing revenue stream, nor can it be certain that it will receive significant revenue before additional cash is required. As a result, there can be no guarantee that the Company will have sufficient capital to fund its ongoing operations, develop or commercialize its products without future financing.

The Company's contractual maturities for its financial liabilities are outlined in the table below.

MedMira Inc.

Notes to the unaudited condensed interim consolidated financial statements

For the six months ended January 31, 2017 and January 31, 2016

In Canadian dollars

**For the period ended January 31, 2017**

	Total	Less than 1 year	1 to 3 years	4 to 5 years	After 5 years
	\$		\$	\$	\$
Loans	6,244,382	5,958,455	285,927	-	-
Accounts payable and accrued liabilities	2,252,061	2,252,061	-	-	-
<b>Total debt</b>	<b>8,496,443</b>	<b>8,210,516</b>	<b>285,927</b>	-	-

**For the year ended July 31, 2016**

	Total	Less than 1 year	1 to 3 years	4 to 5 years	After 5 years
	\$	\$	\$	\$	\$
Loans	6,249,510	5,994,445	255,065	-	-
Accounts payable and accrued liabilities	2,241,257	2,241,257	-	-	-
<b>Total debt</b>	<b>8,490,767</b>	<b>8,235,702</b>	<b>255,065</b>	-	-

The payments noted above do not include interest payments.

## 9. Royalty provision

During March 2015, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future US sales of the Reveal G4 product for a five year period commencing on the day of the first full payment of at least CAD \$100,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$270,000 to fund costs required to complete product development and obtain US Food and Drug Administration (FDA) pre-market approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$270,000 was recorded in equity. As at January 31, 2017, the Company's best estimate of the fair value of the provision was \$38,110 (2016 - \$31,991), which is recorded in accounts payable and accrued liabilities as it is currently payable and the change in fair value of the provision recorded in finance cost.

During July 2016, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future sales of HCV portion of the approved Multiplo HIV/HCV commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$200,000 to fund costs required to complete product development and obtain FDA pre-market approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$200,000 was recorded in equity. As at January 31, 2017, the Company's best estimate of the fair value of the provision was zero.

During October 2016, the Company entered into a royalty agreement with Ritec AG whereby Ritec AG would receive a 12.5% royalty on all future sales of the approved Reveal G4 CLIA product commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, Ritec AG will provide the company with CHF 1,000,000 to fund costs required to complete the product development, clinical trials and obtain FDA approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as Ritec AG is owned by a shareholder of MedMira Holding AG who is the controlling shareholder of the Company, the \$1,310,100 was recorded in equity. At at January 31, 2017, the Company's best estimate of the fair value of the provision was zero.



MedMira Inc.

Notes to the unaudited condensed interim consolidated financial statements

For the six months ended January 31, 2017 and January 31, 2016

In Canadian dollars

## 10. Related parties

The following transactions were recorded with related parties during the six months ended January 31, 2017:

- Director fees totalling \$10,000 were incurred (July 31, 2016 - \$14,166).
- Long term loans totalling \$30,000 were received from the Chief Operating Officer (July 31, 2016 - \$0).
- A royalty agreement was entered into with Ritec AG valued at \$1,310,100 (July 31, 2016 - \$0).

The following balances with related parties were outstanding at January 31, 2017:

- A long term loan totalling \$242,427 was due to the Chief Financial Officer (July 31, 2016 – \$241,565).
- Accounts payable totalling \$68,505 was due to an officer (July 31, 2016 - \$26,901).
- A royalty provision was owed to MedMira Holding AG of \$38,110 (July 31, 2016 – \$31,991).
- A long term loan totalling \$30,000 was due to the Chief Operating Officer (July 31, 2016 - \$0)
- Accounts payable totalling \$20,000 were due to directors (July 31, 2016 - \$10,000)

## 11. Research and development

The Company receives government grants to offset the cost of developing certain products. These grants are recognized as a credit against the research expense in the period the expense is incurred. There are no unfulfilled conditions regarding the grants.

In addition to grants, the Company receives revenue related to a contract with the US military. Research expenses related to the US military contract are recognized in service cost of sales when the revenue is earned. During the six months ended January 31, 2017, none of the research costs incurred were recognized in service cost of sales (January 31, 2016 – \$2,016,265).

The following table provides a summary of aggregate research costs and reimbursements.

	for the three months ended		for the six months ended	
	31-Jan-17	31-Jan-16	31-Jan-17	31-Jan-16
	\$	\$	\$	\$
Research and development (R&D) expenses	(58,011)	1,227,914	108,673	2,760,678
Less: R&D allocated to cost of sales	-	1,063,632	-	2,016,265
<b>Net research and development expense</b>	<b>(58,011)</b>	<b>164,282</b>	<b>108,673</b>	<b>744,413</b>

**12. Expenses by nature**

The following table provides the Company's expenses listed by the nature of the expense.

	for the three months ended		for the six months ended	
	31-Jan-17	31-Jan-16	31-Jan-17	31-Jan-16
	\$	\$	\$	\$
Investment income	-	245	-	366
Change in inventory	(38,678)	(43,849)	(121,251)	(114,043)
Employee benefits	(514,810)	(624,143)	(1,051,957)	(1,163,329)
Depreciation	(26,509)	(25,044)	(49,542)	(49,341)
Distribution	(24,181)	(23,494)	(38,178)	(49,606)
Facility	(100,018)	(110,743)	(179,428)	(205,182)
Professional services	(68,632)	(1,074,882)	(113,301)	(2,251,309)
Lab supplies	(11,889)	(45,989)	(29,991)	(103,672)
Other expenses	138,156	(186,346)	59,694	(512,071)
Exchange gains (losses)	24,110	(51,101)	(18,221)	(60,517)
Finance costs	(120,729)	(166,548)	(215,059)	(357,150)
	<u>(743,180)</u>	<u>(2,351,894)</u>	<u>(1,757,234)</u>	<u>(4,865,854)</u>